AstraZeneca has appointed Dr Jamie Freedman as its new head of oncology, succeeding Dr Mondher Mahjoubi.
Dr Freedman moves to AstraZeneca from its subsidiary MedImmune, where he was senior vice president of global clinical development, with responsibility for leading AstraZeneca’s biologics portfolio.
Prior to this, Dr Freedman served as GlaxoSmithKline’s vice president of oncology R&D, and led OPKO Health’s R&D department.
He also brings experience from biotech Locus Pharmaceuticals, where he was president, chief executive officer and chief medical officer, and Merck & Co, where he held several leadership roles in clinical pharmacology, oncology and experimental medicines.